Ankylosing Spondylitis is a type of arthritis that primarily affects the spine and pelvis.
Mannose–binding lectin (MBL) deficiency and tuberculosis infection in patients with ankylosing spondylitis (AS). We found a significant association between MBL deficiency and higher risk of tuberculosis and urinary tract infection in patients with AS. PubMed, Clin Rheumatol, 09/06/2017. (Also see Extrapulmonary Tuberculosis)
Effectiveness of exercise programs in ankylosing spondylitis (AS): A meta–analysis of randomized controlled trials. Despite the small number of patients and the heterogeneity of exercise programs in this meta–analysis, its results support the potential of exercise programs to improve disease activity and body function in AS. PubMed, Arch Phys Med Rehabil, 08/28/2017.
Prevalence of cardiovascular–related (CVD) comorbidity in ankylosing spondylitis (AS), psoriatic arthritis (PsA) and psoriasis (Ps) in primary care: a matched retrospective cohort study. Our findings provide UK comparisons of CVD–related comorbidities in patients with AS, PsA and Ps alone, which further supports the argument for more evidence in the need for screening and intervention around CVD comorbidities in inflammatory conditions. PubMed, Clin Rheumatol, 08/02/2016. (Also see Psoriasis and Psoriatic Arthritis)
Effect of secukinumab on patient–reported outcomes in patients with active ankylosing spondylitis: A Phase 3 randomized trial (MEASURE 1). Secukinumab provided significant and sustained improvements in health–elated quality of life, and reduced functional impairment, fatigue, and impact of disease on work productivity in patients with active AS. PubMed, Arthritis Rheumatol, 07//07/2016.
Spinal fractures in patients with ankylosing spondylitis. The aim of this review article was to provide the required clinical knowledge that radiologists need to know and the relevant radiological semiotics that clinicians require in diagnosing clinically significant injury to the ankylosed spine. PubMed, Rheumatol Int, 07/05/2016.
The effectiveness of a real life dose reduction strategy for TNF inhibitors in ankylosing spondylitis (AS) and psoriatic arthritis (PsA). In a real–world setting, 60% of individuals with severe AS and PsA who achieve low disease activity can successfully reduce the dose of TNF inhibitor therapy by a third for a mean of 1 year. PubMed, Rheumatology (Oxford), 06/28/2016. (Also see Psoriasis and Psoriatic Arthritis)
Vitamin D, disease activity and comorbidities in early spondyloarthritis. In early axial spondyloarthritis vitamin D deficiency was associated with higher disease activity and severity and presence of metabolic syndrome. PubMed, Clin Exp Rheumatol, 04/05/2016. (Also see Vitamin D)
Effectiveness of ultrasound treatment applied with exercise therapy on patients with ankylosing spondylitis: a double–blind, randomized, placebo–controlled trial. The study showed that ultrasound treatment increases the effect of exercise in patients with ankylosing spondylitis. PubMed, Rheumatol Int, 02/29/2016.
The role of biomechanical factors in ankylosing spondylitis (AS): the patient’s perspective. Patients report physical trauma, exercise and physiotherapy as potential triggers for AS symptoms and these findings further support the experimental evidence for the role of biomechanical factors in disease. Rheumatismo, 02/11/2016.
(Case Report) Coexistence of Ankylosing Spondylitis (AS) With Morphea. Morphea and AS with an inflammatory background and active immunity can exist in the same patient and recent studies have showed the importance of Th17 and associated cytokines in the pathogenesis of these two diseases. Archives of Rheumatology. (Also see Morphea and Causes of Scleroderma: Cytokines)
Many thanks to our recent donors, Jack and Elizabeth Lewis, Chris Dokter, Margaret Roof, Network for Good, PayPal Charitable Giving Fund, United Way Snohomish and Arnold Slotkin. See ISN News for more donors. Click Here to Donate.
TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses.
We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: